Olefin ring-closing metathesis as a powerful tool in drug discovery and development - potent macrocyclic inhibitors of the hepatitis C virus NS3 protease

被引:40
作者
Tsantrizos, Youla S.
Ferland, Jean-Marie
McClory, Andrew
Poirier, Martin
Farina, Vittorio
Yee, Nathan K.
Wang, Xiaojun
Haddad, Nizar
Wei, Xudong
Xu, Jinghua
Zhang, Li
机构
[1] Boehringer Ingelheim Canada Ltd, Res & Dev, Laval, PQ H7S 2G5, Canada
[2] Boehringer Ingelheim Pharmaceut Inc, Dept Chem Dev, Ridgefield, CT 06877 USA
关键词
D O I
10.1016/j.jorganchem.2006.09.027
中图分类号
O61 [无机化学];
学科分类号
070301 ; 081704 ;
摘要
Peptidomimetic inhibitors of the hepatitis C NS3 protease often exhibit poor biopharmaceutical properties. Structure modification of a substrate-based tripeptide into a beta-strand 15-membered ring scaffold provided a new class of peptidomimetics that are significantly superior as drug candidates to their acyclic precursors. Tripeptide dienes composed of three unnatural amino acid residues with numerous chiral centers were efficiently converted to macrocyclic peptides, in high diastereomeric purity, using ring-closing metathesis (RCM). The conformation of the acyclic diene and the protocol for the RCM reaction were investigated and optimized extensively in order to achieve an efficient synthesis of potential therapeutic agents for the treatment of hepatitis C infections. These studies provided the fist small molecule (BILN 2061) that was clinically validated for the treatment of hepatitis C infection in man and opened the door to a plethora of new pre-clinical pharmaceutical agents that can be made in multi kilogram quantities using RCM chemistry. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:5163 / 5171
页数:9
相关论文
共 85 条
[41]  
LLINASBRUNET M, Patent No. 2003064455
[42]  
LLINASBRUNET M, Patent No. 2005028501
[43]  
LLINASBRUNET M, Patent No. 2004037855
[44]   Protein-protein interactions as targets for antiviral chemotherapy [J].
Loregian, A ;
Marsden, HS ;
Palù, G .
REVIEWS IN MEDICAL VIROLOGY, 2002, 12 (04) :239-262
[45]   Design, synthesis, and biological evaluation of HIV/FIV protease inhibitors incorporating a conformationally constrained macrocycle with a small P3′ residue [J].
Mak, CC ;
Le, VD ;
Lin, YC ;
Elder, JH ;
Wong, CH .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (02) :219-222
[46]   SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells [J].
Malcolm, BA ;
Liu, R ;
Lahser, F ;
Agrawal, S ;
Belanger, B ;
Butkiewicz, N ;
Chase, R ;
Gheyas, F ;
Hart, A ;
Hesk, D ;
Ingravallo, P ;
Jiang, C ;
Kong, R ;
Lu, J ;
Pichardo, J ;
Prongay, A ;
Skelton, A ;
Tong, X ;
Venkatraman, S ;
Xia, E ;
Girijavallabhan, V ;
Njoroge, FG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) :1013-1020
[47]   Template-directed ring-closing metathesis: Synthesis and polymerization of unsaturated crown ether analogs [J].
Marsella, MJ ;
Maynard, HD ;
Grubbs, RH .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION IN ENGLISH, 1997, 36 (10) :1101-1103
[48]   CYCLOPROPANES AS CONFORMATIONALLY RESTRICTED PEPTIDE ISOSTERES - DESIGN AND SYNTHESIS OF NOVEL COLLAGENASE INHIBITORS [J].
MARTIN, SF ;
OALMANN, CJ ;
LIRAS, S .
TETRAHEDRON, 1993, 49 (17) :3521-3532
[49]  
MCPHEE F, Patent No. 2004094452
[50]   Remote effects in macrolide formation through ring-forming olefin metathesis: An application to the synthesis of fully active epothilone congeners [J].
Meng, DF ;
Su, DS ;
Balog, A ;
Bertinato, P ;
Sorensen, EJ ;
Danishefsky, SJ ;
Zheng, YH ;
Chou, TC ;
He, LF ;
Horwitz, SB .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1997, 119 (11) :2733-2734